Stock Track | Charles River Laboratories Soars 8.15% in Pre-Market on Q2 Earnings Beat and Raised Guidance

Stock Track

Aug 05

Shares of Charles River Laboratories (CRL) surged 8.15% in pre-market trading on Wednesday after the contract drug developer reported better-than-expected second-quarter results and raised its full-year profit forecast.

The company posted adjusted earnings per share of $3.02, surpassing the consensus estimate of $2.74, while revenue of $1.004 billion beat the expected $975.7 million. The strong performance was driven by improving demand in its Discovery and Safety Assessment segment and better-than-expected results in the Manufacturing segment.

Additionally, Charles River lifted its 2026 adjusted EPS guidance to a range of $11.15 to $11.45, up from a prior view of $10.80 to $11.30 and above the FactSet consensus of $11.11. CEO Birgit Girshick noted that the demand environment continued to strengthen, with broad-based improvement across global biopharmaceutical and biotechnology clients, signaling a recovery from the post-pandemic slowdown.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1170428535"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1170428535\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1170428535?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-05 20:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1170428535","market":"sg","top_or_hot":-1,"title":"Stock Track | Charles River Laboratories Soars 8.15% in Pre-Market on Q2 Earnings Beat and Raised Guidance","media":"Stock Track","content":"<p>Shares of Charles River Laboratories (CRL) surged 8.15% in pre-market trading on Wednesday after the contract drug developer reported better-than-expected second-quarter results and raised its full-year profit forecast.</p><p>The company posted adjusted earnings per share of $3.02, surpassing the consensus estimate of $2.74, while revenue of $1.004 billion beat the expected $975.7 million. The strong performance was driven by improving demand in its Discovery and Safety Assessment segment and better-than-expected results in the Manufacturing segment.</p><p>Additionally, Charles River lifted its 2026 adjusted EPS guidance to a range of $11.15 to $11.45, up from a prior view of $10.80 to $11.30 and above the FactSet consensus of $11.11. CEO Birgit Girshick noted that the demand environment continued to strengthen, with broad-based improvement across global biopharmaceutical and biotechnology clients, signaling a recovery from the post-pandemic slowdown.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Charles River Laboratories Soars 8.15% in Pre-Market on Q2 Earnings Beat and Raised Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Charles River Laboratories Soars 8.15% in Pre-Market on Q2 Earnings Beat and Raised Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-08-05 20:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Charles River Laboratories (CRL) surged 8.15% in pre-market trading on Wednesday after the contract drug developer reported better-than-expected second-quarter results and raised its full-year profit forecast.</p><p>The company posted adjusted earnings per share of $3.02, surpassing the consensus estimate of $2.74, while revenue of $1.004 billion beat the expected $975.7 million. The strong performance was driven by improving demand in its Discovery and Safety Assessment segment and better-than-expected results in the Manufacturing segment.</p><p>Additionally, Charles River lifted its 2026 adjusted EPS guidance to a range of $11.15 to $11.45, up from a prior view of $10.80 to $11.30 and above the FactSet consensus of $11.11. CEO Birgit Girshick noted that the demand environment continued to strengthen, with broad-based improvement across global biopharmaceutical and biotechnology clients, signaling a recovery from the post-pandemic slowdown.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRL","symbol_name":"查尔斯河","start_time":0,"source_url":"","article_id":"1170428535","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1170428535","pubTimestamp":1785932187,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Charles River Laboratories (CRL) surged 8.15% in pre-market trading on Wednesday after the contract drug developer reported better-than-expected second-quarter results and raised its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CRL":"查尔斯河"},"translate_title":"股票跟踪 | Charles River Laboratories 第二季度盈利超出预期并上调指引，盘前股价飙升 8.15%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRL":1},"content_text":"Shares of Charles River Laboratories (CRL) surged 8.15% in pre-market trading on Wednesday after the contract drug developer reported better-than-expected second-quarter results and raised its full-year profit forecast.The company posted adjusted earnings per share of $3.02, surpassing the consensus estimate of $2.74, while revenue of $1.004 billion beat the expected $975.7 million. The strong performance was driven by improving demand in its Discovery and Safety Assessment segment and better-than-expected results in the Manufacturing segment.Additionally, Charles River lifted its 2026 adjusted EPS guidance to a range of $11.15 to $11.45, up from a prior view of $10.80 to $11.30 and above the FactSet consensus of $11.11. CEO Birgit Girshick noted that the demand environment continued to strengthen, with broad-based improvement across global biopharmaceutical and biotechnology clients, signaling a recovery from the post-pandemic slowdown.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}